Search
Treprostinil
go.drugbank.com/drugs/DB00374ApprovedInvestigationalTreprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension. … However, the use of epoprostenol is limited due to its short half-life (3-5 min) and instability at room temperature.
Alteplase
go.drugbank.com/drugs/DB00009ApprovedInvestigationalIn the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin. … [A252270] The use of alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and stenting.
Synonyms: t-PA, t-plasminogen activatorSotrovimab
go.drugbank.com/drugs/DB16355ApprovedInvestigational[L34425, L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective. … found to reduce the risk of death or hospitalization in high-risk adults with COVID-19 in the outpatient setting.
Bevacizumab
go.drugbank.com/drugs/DB00112ApprovedInvestigational[A286054] In 2004, bevacizumab (Avastin) gained FDA approval and became the first antiangiogenic agent introduced to the market, indicated in combination with chemotherapy regimens specific to the type … [A286054] This off-label practice was formalized with the approval of Lytenava (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK), the first ophthalmic formulation of bevacizumab developed specifically
Categories: VEGF/VEGFR (Vascular Endothelial Growth Factor / -Receptor) inhibitorsProducts: ABXEDA EGadofosveset trisodium
go.drugbank.com/drugs/DB06705ApprovedThe agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of the heart and blood vessels.
Nitroglycerin
go.drugbank.com/drugs/DB00727ApprovedInvestigational[L42445] It is also used to induce intraoperative hypotension.[L7099] … [A180166,A180172] Its use as a treatment for angina dates back to 1879 and is still used to treat and prevent angina.[A249970] Nitroglycerin causes vasodilation in both arteries and veins.
Products: NITROGLICERINA PH&TLerodalcibep
go.drugbank.com/drugs/DB19071ApprovedInvestigational[A275273] Lerodalcibep prevents the actions of PCSK9 and allows more LDL to bind to LDLR and be cleared from circulation. … [L54738] Approved by the FDA on December 15, 2025, lerodalcibep is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia
Synonyms: Engineered binding protein (1-96) anti-(human proprotein convertase subtilisin/kexin type 9), derived from human tenth fibronectin type iii domain, fused via peptidyl linker (97gsgsgs102) to human serumGadoteridol
go.drugbank.com/drugs/DB00597ApprovedInvestigationalgadolinium in the brain. … with abnormal vascularity or those thought to disrupt the normal blood-brain barrier.
Ursodeoxycholic acid
go.drugbank.com/drugs/DB01586ApprovedInvestigational[A256272] UDCA works by replacing the hydrophobic or more toxic bile acids from the bile acid pool.[A256272] … [A256267,A256463] UDCA was first characterized in the bile of the Chinese black bear and is formed by 7b-epimerization of [chenodeoxycholic acid], which is a primary bile acid.
Products: T-RUXICOMitapivat
go.drugbank.com/drugs/DB16236ApprovedInvestigationalIt works to increase the activity of erythrocyte pyruvate kinase, a key enzyme involved in the survival of red blood cells. … Defects in the pyruvate kinase enzyme in various red blood cells disorders lead to the lack of energy production for red blood cells, leading to lifelong premature destruction of red blood cells or chronic